Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
Massimo AgliettaVanna Chiarion SileniPaolo FavaMassimo GuidoboniRoberta DepenniAlessandro MinisiniFrancesca ConsoliPaolo AsciertoGaetana RinaldiMaria BanziRiccardo MarconciniRossana GueliVirginia FerraresiMarco TucciGiuseppe ToniniGiovanni Lo ReMichele GuidaMichele Del VecchioIlaria Gioia MarconPaola QueiroloPublished in: Targeted oncology (2021)
Treatment of BRAF V600E-mutant metastatic melanoma with dab + tram in the real-world setting was effective and safe, including the unselected population with several patients having a high tumor burden - concordant with the results of the pivotal phase 3 studies of dab + tram.